Table 1.
Demographic and clinical features reported for 277 patients reported to have CAPA for whom patient-level details are available
| Characteristic | |
|---|---|
| Age (y), median (IQR) | 65 (55–74)a |
| Male sex, n/N (%) | 125/172 (67.8%) |
| Immune compromised, n (%)b | 17 (6.7%) |
| Any immunomodulation, n/N (%) | 154/220 (70%) |
| Systemic steroids, n/N (%) | 136/220 (64.8%)c |
| Tocilizumab, n/N (%) | 35/220 (15.9%) |
| Anakinra, n/N (%) | 2/220 (0.9%) |
| Invasive mechanical ventilation, n (%) | 233 (90.7%) |
| ECMO, n/N (%) | 11/262 (4.2%) |
| Radiographic findings of nodules, n/N (%) | 23/208 (11.1%)d |
| Radiographic findings of cavitations, n (%) | 22 (10.6%) |
| Radiographic findings of nodules or cavitations, or reported as suspicious for fungal infection, n/N (%) | 41/208 (19.7%) |
| Bronchoscopy, n/N (%) | 127/155 (45.8%) |
| Tracheobronchial abnormalities, n/N (%) | 4/127 (3.1%) |
| Mould-active antifungals, n/N (%) | 177/262 (67.6%) |
| Deaths, n/N (%) | 147/248 (59.3%) |
| Timing of CAPA diagnosis after ICU admission (d), median (IQR)b | 8 (5–14)e |
| Length of mechanical ventilation before CAPA diagnosis (d), median (IQR) | 6 (3–10)f |
CAPA, COVID-19–associated pulmonary aspergillosis; ECMO, extracorporeal membrane oxygenation; ICU, intensive care unit; IQR, interquartile range.
a
Data missing for 25 patients.
b
Per European Organization for Research and Treatment of Cancer–Mycoses Study Group Education and Research Consortium consensus definitions for host factors.
c
Plus four already on steroids.
d
One additional patient had nodules attributed to known pulmonary metastases.
e
Data missing for 168 patients.
f
Data missing for 176 patients.